Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | EVP R&D, Chief Medical Officer | September 01, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 65,389 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 5,000 · Balance 74,389 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Row 2 · 2026-09-01 · Sale · Disposed 9,000 · Balance 65,389 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.59 · Expires 2032-02-18 | Direct | 61,276 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Disposed 5,000 · Balance 61,276 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4: These options are fully vested in accordance with their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
F4: These options are fully vested in accordance with their terms.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBIREO PHARMA, INC.
Report date March 02, 2023 · Filed March 02, 2023
Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-02 · Disposition to issuer · Disposed 10,495 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share"). F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F5: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share").
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time").
F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027;
F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.
F5: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2020 Filed Feb 18, 2020 21:10 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,172 | $17.77 | $20,826.44 |
DisclosureSEC source: 0001127602-20-006020 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,080 Read SEC document |
| February 16, 2020 Filed Feb 18, 2020 21:10 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006020 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 21:13 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 1,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-021257 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 6/7/18. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 6/7/18. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 21:13 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 368 | $22.83 | $8,401.44 |
DisclosureSEC source: 0001127602-19-021257 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 21:13 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-021257 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:26 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 27,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008124 · form4.xml · derivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Ordinary Shares · 27,500 shares Expires not disclosed F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:26 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 106,700 | $0.00 Strike: $32.57 | $0.00 |
DisclosureSEC source: 0001127602-19-008124 · form4.xml · derivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,700 Underlying: Ordinary Shares · 106,700 shares Expires 2029-02-21 F1 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/21/2020. Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 00:03 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006972 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 Underlying: Ordinary Shares · 3,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 00:03 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,083 | $32.54 | $35,240.82 |
DisclosureSEC source: 0001127602-19-006972 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,995 Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 00:03 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006972 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:43 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,178 | $34.01 | $40,063.78 |
DisclosureSEC source: 0001127602-18-035957 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,703 Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:43 UTC | Alkermes plc. ALKS · Entity 2392 | GrantOrdinary Shares | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-035957 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,881 F1 · price: These shares were acquired by the reporting person as a result of the partial vesting of performance-vesting restricted stock units granted to the reporting person on February 17, 2017. The vesting of this portion of the performance-vesting restricted stock units was triggered by ALKS 3831 achieving the pre-specified primary efficacy endpoints in each of two phase 3 studies. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 21:31 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 1,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020524 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Ordinary Shares · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 6/7/18. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 6/7/18. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 21:31 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 369 | $48.30 | $17,822.70 |
DisclosureSEC source: 0001127602-18-020524 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881 Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 21:31 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020524 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:03 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 54,500 | $0.00 Strike: $67.26 | $0.00 |
DisclosureSEC source: 0001127602-18-007604 · form4.xml · derivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 Underlying: Ordinary Shares · 54,500 shares Expires 2028-02-16 F2 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/16/2019. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:03 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 13,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007604 · form4.xml · derivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · SVP, Med Dev/Med Affairs, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Ordinary Shares · 13,500 shares Expires not disclosed F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.